Physiological functions of tumor necrosis factor and the consequences of its pathologic overexpression or blockade: Mouse models

Cytokine and Growth Factor Reviews

Volumn 19, Issue 3-4, 2008, Pages 231-244

  Kruglov, Andrei A ^a,b,c   Kuchmiy, Anna ^a,b   Grivennikov, Sergei I ^a,b,d   Tumanov, Alexei V ^a,b,e   Kuprash, Dmitry V ^a,b   Nedospasov, Sergei A ^a,b,c  

^a ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^b MOSCOW STATE UNIVERSITY   (Russian Federation)

^c DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

Anti cytokine therapy; Disease models; Knockout; Transgenic mice

Indexed keywords

CYTOKINE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ANTINEOPLASTIC ACTIVITY; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; ENTERITIS; GENE TARGETING; HOST RESISTANCE; IMMUNE RESPONSE; IMMUNOLOGY; IMMUNOREGULATION; INFLAMMATION; KNOCKOUT MOUSE; LYMPHOCYTE; LYMPHOID TISSUE; MOUSE; NONHUMAN; PEYER PATCH; PHENOTYPE; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; SPLEEN; TRANSGENIC MOUSE; TREATMENT PLANNING;

ANIMALS; AUTOIMMUNE DISEASES; GENE TARGETING; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MODELS, ANIMAL; TUMOR NECROSIS FACTOR-ALPHA;

MUS; MUS MUSCULUS;

EID: 44749088915     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2008.04.010     Document Type: Article

References (133)

1. Carswell E.A., Old L.J., Kassel R.L., Green S., Fiore N., and Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72 (1975) 3666-3670
2. Beutler B., Greenwald D., Hulmes J.D., Chang M., Pan Y.C., Mathison J., et al. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 316 (1985) 552-554
3. Takeuchi O., Hoshino K., Kawai T., Sanjo H., Takada H., Ogawa T., et al. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 11 (1999) 443-451
4. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10 (1992) 411-452
5. Tracey K.J., Fong Y., Hesse D.G., Manogue K.R., Lee A.T., Kuo G.C., et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330 (1987) 662-664
6. Bean A.G., Roach D.R., Briscoe H., France M.P., Korner H., Sedgwick J.D., et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol 162 (1999) 3504-3511
7. Flynn J.L., Goldstein M.M., Chan J., Triebold K.J., Pfeffer K., Lowenstein C.J., et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2 (1995) 561-572
8. Keffer J., Probert L., Cazlaris H., Georgopoulos S., Kaslaris E., Kioussis D., et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 10 (1991) 4025-4031
9. Liu J., Marino M.W., Wong G., Grail D., Dunn A., Bettadapura J., et al. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med 4 (1998) 78-83
10. Marino M.W., Dunn A., Grail D., Inglese M., Noguchi Y., Richards E., et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci USA 94 (1997) 8093-8098
11. Pasparakis M., Alexopoulou L., Episkopou V., and Kollias G. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 184 (1996) 1397-1411
12. Peschon J.J., Torrance D.S., Stocking K.L., Glaccum M.B., Otten C., Willis C.R., et al. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 160 (1998) 943-952
13. Probert L., Akassoglou K., Kassiotis G., Pasparakis M., Alexopoulou L., and Kollias G. TNF-alpha transgenic and knockout models of CNS inflammation and degeneration. J Neuroimmunol 72 (1997) 137-141
14. Kollias G. TNF pathophysiology in murine models of chronic inflammation and autoimmunity. Semin Arthritis Rheum 34 (2005) 3-6
15. Feldmann M., and Maini R.N. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?. Annu Rev Immunol 19 (2001) 163-196
16. Cerami A., and Beutler B. Cachectin: the dark side of tumor necrosis factor. Cold Spring Harb Symp Quant Biol 51 Pt 1 (1986) 625-629
17. Kollias G., and Kontoyiannis D. Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments. Cytokine Growth Factor Rev. 13 (2002) 315-321
18. Toussirot E., and Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an update. Expert Opin Pharmacother 8 (2007) 2089-2107
19. Pfeffer K., Matsuyama T., Kundig T.M., Wakeham A., Kishihara K., Shahinian A., et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73 (1993) 457-467
20. Rothe J., Lesslauer W., Lotscher H., Lang Y., Koebel P., Kontgen F., et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364 (1993) 798-802
21. Paul N.L., and Ruddle N.H. Lymphotoxin. Annu Rev Immunol 6 (1988) 407-438
22. Browning J.L., Ngam-ek A., Lawton P., DeMarinis J., Tizard R., Chow E.P., et al. Lymphotoxin beta, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface. Cell 72 (1993) 847-856
23. Crowe P.D., VanArsdale T.L., Walter B.N., Ware C.F., Hession C., Ehrenfels B., et al. A lymphotoxin-beta-specific receptor. Science 264 (1994) 707-710
24. De Togni P., Goellner J., Ruddle N.H., Streeter P.R., Fick A., Mariathasan S., et al. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science 264 (1994) 703-707
25. Sacca R., Cuff C.A., Lesslauer W., and Ruddle N.H. Differential activities of secreted lymphotoxin-alpha3 and membrane lymphotoxin-alpha1beta2 in lymphotoxin-induced inflammation: critical role of TNF receptor 1 signaling. J Immunol 160 (1998) 485-491
26. Korner H., Riminton D.S., Strickland D.H., Lemckert F.A., Pollard J.D., and Sedgwick J.D. Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting. J Exp Med 186 (1997) 1585-1590
27. Kuprash D.V., Tumanov A.V., Liepinsh D.J., Koroleva E.P., Drutskaya M.S., Kruglov A.A., et al. Novel tumor necrosis factor-knockout mice that lack Peyer's patches. Eur J Immunol 35 (2005) 1592-1600
28. Taniguchi T., Takata M., Ikeda A., Momotani E., and Sekikawa K. Failure of germinal center formation and impairment of response to endotoxin in tumor necrosis factor alpha-deficient mice. Lab Invest 77 (1997) 647-658
29. Eugster H.P., Muller M., Karrer U., Car B.D., Schnyder B., Eng V.M., et al. Multiple immune abnormalities in tumor necrosis factor and lymphotoxin-alpha double-deficient mice. Int Immunol 8 (1996) 23-36
30. Amiot F., Bellkaid Y., Lebastard M., Ave P., Dautry F., and Milon G. Abnormal organisation of the splenic marginal zone and the correlated leukocytosis in lymphotoxin-alpha and tumor necrosis factor alpha double deficient mice. Eur Cytokine Netw 7 (1996) 733-739
31. Korner H., Cook M., Riminton D.S., Lemckert F.A., Hoek R.M., Ledermann B., et al. Distinct roles for lymphotoxin-alpha and tumor necrosis factor in organogenesis and spatial organization of lymphoid tissue. Eur J Immunol 27 (1997) 2600-2609
32. Kuprash D.V., Alimzhanov M.B., Tumanov A.V., Anderson A.O., Pfeffer K., and Nedospasov S.A. TNF and lymphotoxin beta cooperate in the maintenance of secondary lymphoid tissue microarchitecture but not in the development of lymph nodes. J Immunol 163 (1999) 6575-6580
33. Kuprash D.V., Alimzhanov M.B., Tumanov A.V., Grivennikov S.I., Shakhov A.N., Drutskaya L.N., et al. Redundancy in tumor necrosis factor (TNF) and lymphotoxin (LT) signaling in vivo: mice with inactivation of the entire TNF/LT locus versus single-knockout mice. Mol Cell Biol 22 (2002) 8626-8634
34. Smyth M.J., Kelly J.M., Baxter A.G., Korner H., and Sedgwick J.D. An essential role for tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum. J Exp Med 188 (1998) 1611-1619
35. Moore R.J., Owens D.M., Stamp G., Arnott C., Burke F., East N., et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 5 (1999) 828-831
36. Suganuma M., Okabe S., Marino M.W., Sakai A., Sueoka E., and Fujiki H. Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Res 59 (1999) 4516-4518
37. Calzascia T., Pellegrini M., Hall H., Sabbagh L., Ono N., Elford A.R., et al. TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice. J Clin Invest 117 (2007) 3833-3845
38. Erickson S.L., de Sauvage F.J., Kikly K., Carver-Moore K., Pitts-Meek S., Gillett N., et al. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 372 (1994) 560-563
39. Grell M., Douni E., Wajant H., Lohden M., Clauss M., Maxeiner B., et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83 (1995) 793-802
40. Chen X., Baumel M., Mannel D.N., Howard O.M., and Oppenheim J.J. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J Immunol 179 (2007) 154-161
41. Grell M., Becke F.M., Wajant H., Mannel D.N., and Scheurich P. TNF receptor type 2 mediates thymocyte proliferation independently of TNF receptor type 1. Eur J Immunol 28 (1998) 257-263
42. Kim E.Y., and Teh H.S. TNF type 2 receptor (p75) lowers the threshold of T cell activation. J Immunol 167 (2001) 6812-6820
43. Haridas V., Darnay B.G., Natarajan K., Heller R., and Aggarwal B.B. Overexpression of the p80 TNF receptor leads to TNF-dependent apoptosis, nuclear factor-kappa B activation, and c-Jun kinase activation. J Immunol 160 (1998) 3152-3162
44. Kim E.Y., Priatel J.J., Teh S.J., and Teh H.S. TNF receptor type 2 (p75) functions as a costimulator for antigen-driven T cell responses in vivo. J Immunol 176 (2006) 1026-1035
45. Vandenabeele P., Declercq W., Vercammen D., van de C.M., Grooten J., Loetscher H., et al. Functional characterization of the human tumor necrosis factor receptor p75 in a transfected rat/mouse T cell hybridoma. J Exp Med 176 (1992) 1015-1024
46. Maeda S., Chang L., Li Z.W., Luo J.L., Leffert H., and Karin M. Ikkbeta is required for prevention of apoptosis mediated by cell-bound but not by circulating TNFalpha. Immunity 19 (2003) 725-737
47. Wolf D., Hallmann R., Sass G., Sixt M., Kusters S., Fregien B., et al. TNF-alpha-induced expression of adhesion molecules in the liver is under the control of TNFR1-relevance for concanavalin A-induced hepatitis. J Immunol 166 (2001) 1300-1307
48. Tartaglia L.A., Ayres T.M., Wong G.H., and Goeddel D.V. A novel domain within the 55 kDa TNF receptor signals cell death. Cell 74 (1993) 845-853
49. Tartaglia L.A., Pennica D., and Goeddel D.V. Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J Biol Chem 268 (1993) 18542-18548
50. Li X., Yang Y., and Ashwell J.D. TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature 416 (2002) 345-347
51. Lucas R., Juillard P., Decoster E., Redard M., Burger D., Donati Y., et al. Crucial role of tumor necrosis factor (TNF) receptor 2 and membrane-bound TNF in experimental cerebral malaria. Eur J Immunol 27 (1997) 1719-1725
52. Black R.A., Rauch C.T., Kozlosky C.J., Peschon J.J., Slack J.L., Wolfson M.F., et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385 (1997) 729-733
53. Solomon K.A., Pesti N., Wu G., and Newton R.C. Cutting edge: a dominant negative form of TNF-alpha converting enzyme inhibits proTNF and TNFRII secretion. J Immunol 163 (1999) 4105-4108
54. Grivennikov S.I., Tumanov A.V., Liepinsh D.J., Kruglov A.A., Marakusha B.I., Shakhov A.N., et al. Distinct and nonredundant in vivo functions of TNF produced by t cells and macrophages/neutrophils: protective and deleterious effects. Immunity 22 (2005) 93-104
55. Togbe D., Grivennikov S.I., Noulin N., Couillin I., Maillet I., Jacobs M., et al. T cell-derived TNF down-regulates acute airway response to endotoxin. Eur J Immunol 37 (2007) 768-779
56. Freudenberg M.A., and Galanos C. Tumor necrosis factor alpha mediates lethal activity of killed gram-negative and gram-positive bacteria in d-galactosamine-treated mice. Infect Immun 59 (1991) 2110-2115
57. Lehmann V., Freudenberg M.A., and Galanos C. Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and d-galactosamine-treated mice. J Exp Med 165 (1987) 657-663
58. Ruuls S.R., Hoek R.M., Ngo V.N., McNeil T., Lucian L.A., Janatpour M.J., et al. Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity 15 (2001) 533-543
59. Alexopoulou L., Kranidioti K., Xanthoulea S., Denis M., Kotanidou A., Douni E., et al. Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation and autoimmunity. Eur J Immunol 36 (2006) 2768-2780
60. Miethke T., Wahl C., Heeg K., Echtenacher B., Krammer P.H., and Wagner H. T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor. J Exp Med 175 (1992) 91-98
61. Fast D.J., Schlievert P.M., and Nelson R.D. Toxic shock syndrome-associated staphylococcal and streptococcal pyrogenic toxins are potent inducers of tumor necrosis factor production. Infect Immun 57 (1989) 291-294
62. Bette M., Schafer M.K., van Rooijen N., Weihe E., and Fleischer B. Distribution and kinetics of superantigen-induced cytokine gene expression in mouse spleen. J Exp Med 178 (1993) 1531-1539
63. Musicki K., Briscoe H., Tran S., Britton W.J., and Saunders B.M. Differential requirements for soluble and transmembrane tumor necrosis factor in the immunological control of primary and secondary Listeria monocytogenes infection. Infect Immun 74 (2006) 3180-3189
64. Torres D., Janot L., Quesniaux V.F., Grivennikov S.I., Maillet I., Sedgwick J.D., et al. Membrane tumor necrosis factor confers partial protection to listeria infection. Am J Pathol 167 (2005) 1677-1687
65. Narni-Mancinelli E., Campisi L., Bassand D., Cazareth J., Gounon P., Glaichenhaus N., et al. Memory CD8+ T cells mediate antibacterial immunity via CCL3 activation of TNF/ROI+ phagocytes. J Exp Med 204 (2007) 2075-2087
66. Serbina N.V., Salazar-Mather T.P., Biron C.A., Kuziel W.A., and Pamer E.G. TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection. Immunity 19 (2003) 59-70
67. Armaka M., Apostolaki M., Jacques P., Kontoyiannis D.L., Elewaut D., and Kollias G. Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J Exp Med 205 (2008) 331-337
68. Schumann J., Muhlen K., Kiemer A.K., Vollmar A.M., and Tiegs G. Parenchymal, but not leukocyte TNF receptor 2 mediates T cell-dependent hepatitis in mice. J Immunol 170 (2003) 2129-2137
69. Kusters S., Tiegs G., Alexopoulou L., Pasparakis M., Douni E., Kunstle G., et al. In vivo evidence for a functional role of both tumor necrosis factor (TNF) receptors and transmembrane TNF in experimental hepatitis. Eur J Immunol 27 (1997) 2870-2875
70. Bonder C.S., Ajuebor M.N., Zbytnuik L.D., Kubes P., and Swain M.G. Essential role for neutrophil recruitment to the liver in concanavalin A-induced hepatitis. J Immunol 172 (2004) 45-53
71. Mercer J.C., Ragin M.J., and August A. Natural killer T cells: rapid responders controlling immunity and disease. Int J Biochem Cell Biol 37 (2005) 1337-1343
72. Neumann B., Luz A., Pfeffer K., and Holzmann B. Defective Peyer's patch organogenesis in mice lacking the 55-kDa receptor for tumor necrosis factor. J Exp Med 184 (1996) 259-264
73. Adachi S., Yoshida H., Honda K., Maki K., Saijo K., Ikuta K., et al. Essential role of IL-7 receptor alpha in the formation of Peyer's patch anlage. Int Immunol 10 (1998) 1-6
74. Eberl G., Marmon S., Sunshine M.J., Rennert P.D., Choi Y., and Littman D.R. An essential function for the nuclear receptor RORgamma(t) in the generation of fetal lymphoid tissue inducer cells. Nat Immunol 5 (2004) 64-73
75. Mebius R.E. Organogenesis of lymphoid tissues. Nat Rev Immunol 3 (2003) 292-303
76. Meier D., Bornmann C., Chappaz S., Schmutz S., Otten L.A., Ceredig R., et al. Ectopic lymphoid-organ development occurs through interleukin 7-mediated enhanced survival of lymphoid-tissue-inducer cells. Immunity 26 (2007) 643-654
77. Yoshida H., Honda K., Shinkura R., Adachi S., Nishikawa S., Maki K., et al. IL-7 receptor alpha+ CD3(-) cells in the embryonic intestine induces the organizing center of Peyer's patches. Int Immunol 11 (1999) 643-655
78. Tumanov A.V., Kuprash D.V., Mach J.A., Nedospasov S.A., and Chervonsky A.V. Lymphotoxin and TNF produced by B cells are dispensable for maintenance of the follicle-associated epithelium but are required for development of lymphoid follicles in the Peyer's patches. J Immunol 173 (2004) 86-91
79. Endres R., Alimzhanov M.B., Plitz T., Futterer A., Kosco-Vilbois M.H., Nedospasov S.A., et al. Mature follicular dendritic cell networks depend on expression of lymphotoxin beta receptor by radioresistant stromal cells and of lymphotoxin beta and tumor necrosis factor by B cells. J Exp Med 189 (1999) 159-168
80. Wang Y., Wang J., Sun Y., Wu Q., and Fu Y.X. Complementary effects of TNF and lymphotoxin on the formation of germinal center and follicular dendritic cells. J Immunol 166 (2001) 330-337
81. Tumanov A.V., Kuprash D.V., Lagarkova M.A., Grivennikov S.I., Abe K., Shakhov A.N., et al. Distinct role of surface lymphotoxin expressed by B cells in the organization of secondary lymphoid tissues. Immunity 17 (2002) 239-250
82. Victoratos P., Lagnel J., Tzima S., Alimzhanov M.B., Rajewsky K., Pasparakis M., et al. FDC-specific functions of p55TNFR and IKK2 in the development of FDC networks and of antibody responses. Immunity 24 (2006) 65-77
83. Shakhov A.N., Collart M.A., Vassalli P., Nedospasov S.A., and Jongeneel C.V. Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages. J Exp Med 171 (1990) 35-47
84. Han J., Brown T., and Beutler B. Endotoxin-responsive sequences control cachectin/tumor necrosis factor biosynthesis at the translational level. J Exp Med 171 (1990) 465-475 [published erratum appears in J Exp Med 1990 Mar 1; 171 3 971-2]
85. Biragyn A., and Nedospasov S.A. Lipopolysaccharide-induced expression of TNF-alpha gene in the macrophage cell line ANA-1 is regulated at the level of transcription processivity. J Immunol 155 (1995) 674-683
86. Xanthoulea S., Pasparakis M., Kousteni S., Brakebusch C., Wallach D., Bauer J., et al. Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. J Exp Med 200 (2004) 367-376
87. Probert L., Keffer J., Corbella P., Cazlaris H., Patsavoudi E., Stephens S., et al. Wasting, ischemia, and lymphoid abnormalities in mice expressing T cell-targeted human tumor necrosis factor transgenes. J Immunol 151 (1993) 1894-1906
88. Glosli H., Veiby O.P., Fjerdingstad H., Mehlum A., Probert L., Kollias G., et al. Effects of hTNFalpha expression in T cells on haematopoiesis in transgenic mice. Eur J Haematol 63 (1999) 50-60
89. Akassoglou K., Probert L., Kontogeorgos G., and Kollias G. Astrocyte-specific but not neuron-specific transmembrane TNF triggers inflammation and degeneration in the central nervous system of transgenic mice. J Immunol 158 (1997) 438-445
90. Probert L., Plows D., Kontogeorgos G., and Kollias G. The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice. Eur J Immunol 25 (1995) 1794-1797
91. Zwerina J., Redlich K., Polzer K., Joosten L., Kronke G., Distler J., et al. TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci USA 104 (2007) 11742-11747
92. Kontoyiannis D., Pasparakis M., Pizarro T.T., Cominelli F., and Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 10 (1999) 387-398
93. Franciotta D.M., Grimaldi L.M., Martino G.V., Piccolo G., Bergamaschi R., Citterio A., et al. Tumor necrosis factor in serum and cerebrospinal fluid of patients with multiple sclerosis. Ann Neurol 26 (1989) 787-789
94. Ishizu T., Minohara M., Ichiyama T., Kira R., Tanaka M., Osoegawa M., et al. CSF cytokine and chemokine profiles in acute disseminated encephalomyelitis. J Neuroimmunol 175 (2006) 52-58
95. Grau G.E., Fajardo L.F., Piguet P.F., Allet B., Lambert P.H., and Vassalli P. Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria. Science 237 (1987) 1210-1212
96. Probert L., Akassoglou K., Pasparakis M., Kontogeorgos G., and Kollias G. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. Proc Natl Acad Sci USA 92 (1995) 11294-11298
97. Douni E., and Kollias G. A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin alpha, or the p55TNF-R. J Exp Med 188 (1998) 1343-1352
98. Akassoglou K., Douni E., Bauer J., Lassmann H., Kollias G., and Probert L. Exclusive tumor necrosis factor (TNF) signaling by the p75TNF receptor triggers inflammatory ischemia in the CNS of transgenic mice. Proc Natl Acad Sci USA 100 (2003) 709-714
99. Sicotte N.L., and Voskuhl R.R. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 57 (2001) 1885-1888
100. Kassiotis G., and Kollias G. Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J Exp Med 193 (2001) 427-434
101. Kontoyiannis D., Boulougouris G., Manoloukos M., Armaka M., Apostolaki M., Pizarro T., et al. Genetic dissection of the cellular pathways and signaling mechanisms in modeled tumor necrosis factor-induced Crohn's-like inflammatory bowel disease. J Exp Med 196 (2002) 1563-1574
102. Corazza N., Eichenberger S., Eugster H.P., and Mueller C. Nonlymphocyte-derived tumor necrosis factor is required for induction of colitis in recombination activating gene (RAG)2(-/-) mice upon transfer of CD4(+)CD45RB(hi) T cells. J Exp Med 190 (1999) 1479-1492
103. Neurath M.F., Fuss I., Pasparakis M., Alexopoulou L., Haralambous S., and Meyer zum Buschenfelde K.H. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol 27 (1997) 1743-1750
104. Naito Y., Takagi T., Handa O., Ishikawa T., Nakagawa S., Yamaguchi T., et al. Enhanced intestinal inflammation induced by dextran sulfate sodium in tumor necrosis factor-alpha deficient mice. J Gastroenterol Hepatol 18 (2003) 560-569
105. Garrett W.S., Lord G.M., Punit S., Lugo-Villarino G., Mazmanian S.K., Ito S., et al. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell 131 (2007) 33-45
106. Lipsky P.E., van der Heijde D.M., St Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., et al., Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343 (2000) 1594-1602
107. Weinblatt M.E., Keystone E.C., Furst D.E., Kavanaugh A.F., Chartash E.K., and Segurado O.G. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis 65 (2006) 753-759
108. Weinblatt M.E., Kremer J.M., Bankhurst A.D., Bulpitt K.J., Fleischmann R.M., Fox R.I., et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340 (1999) 253-259
109. Kodama S., Davis M., and Faustman D.L. The therapeutic potential of tumor necrosis factor for autoimmune disease: a mechanistically based hypothesis. Cell Mol Life Sci 62 (2005) 1850-1862
110. Sfikakis P.P., and Kollias G. Tumor necrosis factor biology in experimental and clinical arthritis. Curr Opin Rheumatol 15 (2003) 380-386
111. Elliott M.J., Maini R.N., Feldmann M., Long-Fox A., Charles P., Katsikis P., et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 36 (1993) 1681-1690
112. Mori L., Iselin S., De L.G., and Lesslauer W. Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice. J Immunol 157 (1996) 3178-3182
113. Plessner H.L., Lin P.L., Kohno T., Louie J.S., Kirschner D., Chan J., et al. Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. J Infect Dis 195 (2007) 1643-1650
114. Steed P.M., Tansey M.G., Zalevsky J., Zhukovsky E.A., Desjarlais J.R., Szymkowski D.E., et al. Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science 301 (2003) 1895-1898
115. Zalevsky J., Secher T., Ezhevsky S.A., Janot L., Steed P.M., O'Brien C., et al. Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection. J Immunol 179 (2007) 1872-1883
116. He M.M., Smith A.S., Oslob J.D., Flanagan W.M., Braisted A.C., Whitty A., et al. Small-molecule inhibition of TNF-alpha. Science 310 (2005) 1022-1025
117. Deng G.M., Zheng L., Ka-Ming C.F., and Lenardo M. Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain of tumor necrosis factor receptors. Nat Med 11 (2005) 1066-1072
118. Anolik J.H., Ravikumar R., Barnard J., Owen T., Almudevar A., Milner E.C., et al. Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J Immunol 180 (2008) 688-692
119. Keane J., Remold H.G., and Kornfeld H. Virulent Mycobacterium tuberculosis strains evade apoptosis of infected alveolar macrophages. J Immunol 164 (2000) 2016-2020
120. Mohan V.P., Scanga C.A., Yu K., Scott H.M., Tanaka K.E., Tsang E., et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun 69 (2001) 1847-1855
121. Saliu O.Y., Sofer C., Stein D.S., Schwander S.K., and Wallis R.S. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 194 (2006) 486-492
122. Clausen B.E., Burkhardt C., Reith W., Renkawitz R., and Forster I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res 8 (1999) 265-277
123. Lee P.P., Fitzpatrick D.R., Beard C., Jessup H.K., Lehar S., Makar K.W., et al. A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival. Immunity 15 (2001) 763-774
124. Rickert R.C., Roes J., and Rajewsky K. B lymphocyte-specific Cre-mediated mutagenesis in mice. Nucleic Acids Res 25 (1997) 1317-1318
125. Kuhn R., Schwenk F., Aguet M., and Rajewsky K. Inducible gene targeting in mice. Science 269 (1995) 1427-1429
126. Caton M.L., Smith-Raska M.R., and Reizis B. Notch-RBP-J signaling controls the homeostasis of CD8-dendritic cells in the spleen. J Exp Med 204 (2007) 1653-1664
127. el Marjou F., Janssen K.P., Chang B.H., Li M., Hindie V., Chan L., et al. Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. Genesis 39 (2004) 186-193
128. Plows D., Kontogeorgos G., and Kollias G. Mice lacking mature T and B lymphocytes develop arthritic lesions after immunization with type II collagen. J Immunol 162 (1999) 1018-1023
129. Gekara N.O., and Weiss S. Mast cells initiate early anti-Listeria host defences. Cell Microbiol 10 (2008) 225-236
130. Malaviya R., Ikeda T., Ross E., and Abraham S.N. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha. Nature 381 (1996) 77-80
131. Rijnierse A., Koster A.S., Nijkamp F.P., and Kraneveld A.D. TNF-alpha is crucial for the development of mast cell-dependent colitis in mice. Am J Physiol Gastrointest Liver Physiol 291 (2006) G969-G976
132. Georgopoulos S., Plows D., and Kollias G. Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice. J Inflamm 46 (1996) 86-97
133. Corazza N., Brunner T., Buri C., Rihs S., Imboden M.A., Seibold I., et al. Transmembrane tumor necrosis factor is a potent inducer of colitis even in the absence of its secreted form. Gastroenterology 127 (2004) 816-825